Radiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
|
|
- Eugene Hart
- 5 years ago
- Views:
Transcription
1 Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology
2 O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection of patients?
3 Swedish Rectal Cancer Trial Preop RT Surgery P - value Local Failure 12 % 27 % < Yr Survival 58 % 48 % 0.04 NEJM, 1997
4 TME-Trial: RT+TME vs. TME Local Failure at 5 years: RT+TME: 5.6% TME: 10.9% p < Kapiteijn E et al.,n Engl J Med 2001;345: Peeters K et al., Ann Surg 2007;246:
5 Influence of CRM on LR Preop RT (%) Surgery (%) P-value CRM 2 mm NS CRM > 2 mm <0.001 CRM > 10 mm NS
6 Late toxicity Dutch Trial Faecal incontinence 39% in non-irradiated patients vs 62 % in irradiated patients (p<0.001) Sexual activity in male patients 66% in non-irradiated patients vs 57 % in irradiated patients (p=0.05) Sexual activity in female patients 53% in non-irradiated patients vs 39 % in irradiated patients (p=0.02) No differences in QoL
7 Trial Design Clinically operable adenocarcinoma of the rectum <15cm from anal verge; no metastases PRE Pre-operative RT 25Gy / 5F Surgery Pathology Randomise POST Surgery Pathology CRM-ve CRM+ve No RT Post-op CRT 45Gy / 25F + concurrent 5FU Adjuvant chemotherapy given as per local policy
8 LR by treatment (ITT) LR rate (%) 60 N Events 3yr LR 5yr LR PRE % 5% POST % 17% HR(95%CI)=2.47(1.61, 3.79) p< Number at risk Time(Years) Pre Post
9 DFS by treatment (ITT) DFS rate (% 20 N Events 3yr DFS 5yr DFS PRE % 75% POST % 67% HR(95%CI)=1.31 (1.02, 1.67) p= Time(Years) Pre Post
10 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection of patients?
11 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection of patients?
12 CAO/ARO/AIO-94 Arm I: OP 5-FU 5-FU 5-FU 5-FU 5-FU 5-FU 5 x 1000 mg/m 2 5 x 1000 mg/m mg/m 2 /d 120h-infusion 120h-infusion i.v.-bolus RT: Gy Boost Arm II: 5-FU 5-FU 5 x 1000 mg/m 2 5 x 1000 mg/m 2 120h-infusion 120h-infusion RT: 50.4 Gy OP 5-FU 5-FU 5-FU 5-FU 500 mg/m 2 /d I.v.bolus Weeks Sauer R et al., N Engl J Med 2004; 351:
13 Pre vs. Postop. RCT: CAO/ARO/AIO-94 Cumulative Incidence Local Relapse p = Postop. CRT 13% 6% Preop. RCT Months Preop CRT: + Downstaging Compliance Local control Toxicity Sphincter Sauer R et al., N Engl J Med 2004; 351:
14 Pathological Stage Postop. CRT CAO/ARO/AIO-94 M SM MP UICC- I 18 % UICC-II 29 % UICC-III 40 % Risk of Overtreatment UICC-IV 7 % Missing 6 % Sauer R et al., N Engl J Med 2004; 351:
15 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? RT with new drugs? Selection of patients?
16 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? RT with new drugs? Selection of patients?
17 Polish trial 316 pts RT s ur g er y CT RT Bujko et al, Radiother Oncol 2004
18 Preoperative 5x5 Gy Preoperative RCT 5x5 Gy 50.4 Gy + CT P n=148 n=138 Sphincterpreserved 61% 58% 0.57 T-Category ypt0 1% 16% <0.001 ypt1 2% 9% ypt2 37% 37% ypt3-4 60% 38% N-Category ypn0 52% 68% ypn1 48% 32% CRM + 13% 4% Bujko et al. Radiother Oncol 2004;72:15-24
19 Preoperative 5x5 Gy Preoperative RCT 14.2% 9.0% p=0.17 p=0.8 Bujko et al., Br J Surg 2006;93:
20 An intergroup trial (TROG, AGITG, CSSANZ, RACS) T3NxM0 5 x 5 Gy 5-FU CRT P-value Number of pts year LR rates 7.5% 4.4% year M1 28% 31% year OS 74% 70% 0.56 RTOG 3-4 late tox 7.6% 8.8% 0.84 For distal tumors (< 5 cm), six of 48 SC patients and one of 31 LC patients experienced local recurrence Ngan et al., JCO 2012
21 Preoperative R(C)T Preoperative 5x5Gy (+) Biologic effective dose Combination with CT + + (+) Downsizing Acute toxicity Late toxicity Compliance Costs (+) + +
22 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? Risk-adapted! If downsizing required: CRT or wait RT with new drugs? Selection of patients?
23 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? Risk-adapted! If downsizing required: CRT or wait RT with new drugs? Selection of patients?
24 Rectal cancer T3/T4 NX M0 (UICC 1987) by DRE or EUS Considered resectable, WHO PS 0-1, Age 80 y RANDOMIZE Pre-op RT Pre-op RT + 5FU/LV x2 Pre-op RT Pre-op RT + 5FU/LV x2 Surgery Surgery Surgery Surgery Accrual : 1011 patients April April 2003 Post-op 5FU/LV x4 Post-op 5FU/LV x4
25 DFS OS Bosset et al, Lancet Oncology 2014
26 year of randomisation number of patients preoperative regimen cumulative dose OX preop STAR-01 ACCORD 12 CAO/ARO/ AIO-04 11/ /2008 Oxaliplatin 11/2005-7/2008 7/2006-2/2010 NSABP-R-04 7/2004-8/2010 PETACC-6 11/ / ,4 Gy + fluorouracil 225mg/m² (CI) vs. 50,4 Gy + fluorouracil 225mg/m² (CI) + OX 60mg/m² weekly 45 Gy + CAP b.i.d. 800mg/m² vs. 50 Gy + CAP b.i.d. 800mg/m² + OX 50mg/m² weekly 50,4 Gy + fluorouracil 1000mg/m² d1- d5, d29-d33 vs. 50,4 Gy + fluorouracil 250mg/m² d1- d14, d22-d35 + OX 50mg/m² d1,8,22,29 45 Gy + 5,4-10,8Gy + fluorouracil 225mg/m² (CI) or CAP 825mg/m² b.i.d. vs. 45 Gy + 5,4-10,8Gy + fluorouracil 225mg/m² (CI) or CAP 825mg/m² b.i.d. + OX 50mg/ m² weekly 45 Gy + optional boost 5,4 Gy + CAP b.i.d. 825mg/m² vs. 45 Gy + optional boost 5,4 Gy + CAP b.i.d. 825mg/m² + OX 50mg/m² d1,8,15,22, mg/m² 250mg/m² 200mg/m² 250mg/m² 250mg/m² primary endpoint OS pcr DFS pcr, sphincter saving surgery, downstaging DFS
27 Toxicity data of randomized trials with oxaliplatin G3-4 preop toxicity STAR-01 ACCORD 12 CAO/ARO/ AIO-04 8% vs. 24% 10.9% vs. 25.4% 20% vs. (p<0,001) (p<0,001) 23% NSABP-R-04 6,6% vs. 15,4% (p<0,0001) PETACC-6 15,1% vs. 36,7% surgical toxicities 80% vs. 83% 20.9% vs. 18.1% 44% vs. 47% NA 38% vs. 41% full dose RT 92% vs. 84% 100% vs. 87% 96% vs. 94% Dose 90% vs. 80% 50% vs. 59% 21% vs. modification received 80% 15% CT of fluorouracil and 66% received all OX cycles NA 97% vs. 94% From 84% to 97% of pts received >80% of the ideal CT dose 91% vs. 63% received <90%
28 ACCORD 12 Gerard et al, JCO 2012
29 Disease- free survival: primary analysis (ITT) follow up 31 months ( years) Cox model adjusted for stratification factors (except center) HR = 1.04 ( ) P = year DFS: 74.5% Cape 73.9% Cape+Oxali (years) O N Number of patients at risk : Treatment arm Cape+RT Cape+Oxali+RT
30 Rectal Cancer: Rationale to combine CRT with EGFR-Inhibition: EGFR - EGFR + pcr: 8/35 pcr: 2/52 29% 4% p=0.006 Giralt J. et al., Radiother Oncol 2005;74:101-8
31 N Preoperative Regimen pcr FFCD 762 RT RT/5FU 3.7% 11.7% EORTC 1011 RT RT/5FU 5% 11% Bertolini et al. 40 RT/5-FU/Cetuximab 8% Horisberger et al. 50 RT/irinotecan/capecitabine/cetuximab 8% Machiels et al RT/5-FU RT/Cetuximab/Capecitabine 11% 5% Rodel et al RT/capecitabine/oxaliplatin RT/capecitabine/oxaliplatin + cetuximab 16% 9% RCT: mean pcr= 12% RCT+ cetuximab: mean pcr= 7.5%
32 Pooled pcr = 22% SELECTION! Molecular mechanisms? Biomarkers?
33 RAPIDO trial Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation trial Randomized multicentre Phase III study Arm A = control! Long course chemo-rt (5 weeks) àsurgery à(adjuvant chemo) Pts with primary high risk rectal cancer N = 885 Arm B = exp! 5 x 5Gy! 6 cycles of capecitabine + oxaliplatin àsurgery
34 Brachytherapy Endorectal BT as boost Danish Colorectal Cancer Group Dose-escalation randomized phase III trial Pts with resectable T3 and T4 tumours; CRM 5mm on MRI Standard CRT (50,4 Gy in 28 fx) N = 123 (T3: 102; T4: 21) Standard CRT + HDR brachy boost (10 Gy in 2 fx) N = 120 (T3: 102; T4: 18) Jakobsen et al. IJROBP 2012
35 Brachytherapy T3 tumours TRG 1 and 2 Post-op complications Grade 3 toxicity Higher radiation dose increases the rate of major response (TRG1-2) by 50% in T3 tumours Endorectal boost is feasible, with no significant increase in toxicity or surgical complications Jakobsen et al. IJROBP 2012
36 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? Risk-adapted! If downsizing required: CRT or wait RT with new drugs? Scheduling and intensification requires further study Selection of patients?
37 RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? Risk-adapted! If downsizing required: CRT or wait RT with new drugs? Scheduling and intensification requires further study Selection of patients?
38 Selection of patients!
39 Quality of surgery: definitions Complete mesorectum: No defect deeper than 5 mm Smooth circumferential margin
40 Quality of surgery: definitions Incomplete mesorectum: Defects down onto muscularis Irregular circumferential margin
41 LR by plane of surgery LR rate (%) Events N 3yr LR 5yr LR Mesorectal plane % 8% Intramesorectal plane % 9% Muscularis propria plane % 21% p= Time (years)
42 Fokas et al, JCO 2014
43 Organ preservation Organ preservation is appealing Avoidance of significant postoperative mortality and morbidity long-term urinary, sexual, and fecal dysfunction temporary or definitive stoma Increasing quality of life and oncological outcome seems good Maas et al, JCO 2011
44 Watch-and-wait outcome Habr-Gama series Resectable cancer, <7cm from anal verge ccr + observation (n=71) vs. pcr (n=22) OS DFS 5y OS 100% vs. 88% 5y OS 92% vs. 83% Habr-Gama et al, Ann Surg 2004 Stage 0 has excellent prognosis, irrespective of treatment strategy
45 S U M M A R Y RT with TME surgery? YES! But some subgroups may not benefit Neoadjuvant or adjuvant RT? Neoadjuvant! But need for improved staging (MRI) 5 x 5 Gy or long-course CRT? Risk-adapted! If downsizing required: CRT or wait RT with new drugs? Scheduling and intensification requires further study Selection of patients? YES! Before and during
46 Thank you!
Carcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Valencia May 2018 State of the art: Standards of care in preoperative treatment for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures:
More informationState of the art: Standard(s) of radio/chemotherapy for rectal cancer
State of the art: Standard(s) of radio/chemotherapy for rectal cancer Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Disclosure Advisory Board: Sanofi Oncology, Eli-
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 State of the art: Radio- /chemotherapy for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationNeoadjuvant treatment Evolution and Current Status
Neoadjuvant treatment Evolution and Current Status Dr Andrew See Radiation Oncologist 2017 Rectal Cancer Symposium Friday 10 th November 2017 2 1 Major Randomised Trials Supporting Neoadjuvant CRT Trial
More informationOpportunity for palliative care Research
Opportunity for palliative care Research Role of Radiotherapy in Multidisciplinary Management of Rectal Cancers Dr Sushmita Pathy Associate Professor Department of Radiation Oncology Dr BRA Institute Rotary
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationPreoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
More informationUCL. Rectum Adenocarcinoma. Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans
Rectum Adenocarcinoma Quality of conformal radiotherapy Impact for the surgeon P. Scalliet & K. Haustermans Fifth Belgian Surgical Week May 6th, 2004, Oostende SOR rectum adenocarcinoma Indication of radiotherapy
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationNeues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom
Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom Prof. Dr. med. R. Fietkau Strahlenklinik Disclosure I have the following potential confilct(s) of interest to report: Type of affiliation/ financial
More informationRECTAL CANCER: Adjuvant Therapy. Maury Rosenstein, MD Montefiore Medical Center December 2012
RECTAL CANCER: Adjuvant Therapy Maury Rosenstein, MD Montefiore Medical Center December 2012 Overview Indications for adjuvant therapy Preoperative Postoperative New Advances Epidemiology Approximately
More informationRectal Cancer : Curative treatment without surgery
Rectal Cancer : Curative treatment without surgery Dieter Hahnloser dieter.hahnloser@chuv.ch CHUV University Hospital Lausanne Switzerland Reasons for intervention (surgery) Cure Live longer Feel better
More informationRectal Cancer Update 2008 The Last 5 cm. Consensus Building
Rectal Cancer Update 2008 The Last 5 cm Consensus Building Case Distal Rectal Cancer 65 male physician Rectal mass: 5cm from anal verge, 1cm above sphincter? Imaging choice: CT vs MR vs ERUS? Adjuvant
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38705 holds various files of this Leiden University dissertation. Author: Gijn, Willem van Title: Rectal cancer : developments in multidisciplinary treatment,
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationEarly Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationCurrent Issues and Controversies in the Management of Rectal Cancer
Current Issues and Controversies in the Management of Rectal Cancer Ghazi M. Nsouli MD 11 th Annual Congress of the Lebanese Society of Gastroenterology November 16, 2012 GMN 20121116 1 Staging of rectal
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationPreoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
Evidence-Based Series 2-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with
More informationRadiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationShort-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer
Original Article 1223 Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer Bruce D. Minsky, MD a ; Claus Rödel, MD b ; and Vincenzo Valentini, MD c Abstract The 2 broad approaches
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationMeta analysis in Rectal Cancer
Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology
More informationWhere are we at with organ preservation for rectal cancer? Simon Bach Queen Elizabeth Hospital Birmingham ACPGBI Edinburgh 2016
Where are we at with organ preservation for rectal cancer? Simon Bach Queen Elizabeth Hospital Birmingham ACPGBI Edinburgh 2016 Disclosures Consultant for Johnson and Johnson (Ethicon Inc) Encompasses
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationCRT AND SURGICAL resection are important elements
Current Status and Future Directions in Preoperative Chemoradiotherapy of Rectal Cancer By Claus Rödel, MD Overview: With optimized local treatment for patients with locally advanced rectal cancer, achieved
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon http://journal-arc.jp REVIEW ARTICLE Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer Kazushige Kawai, Soichiro Ishihara, Hiroaki
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationPerioperative versus adjuvant management of gastric cancer, update 2013
Perioperative versus adjuvant management of gastric cancer, update 2013 Cornelis J.H. van de Velde, MD, PhD,FRCPS and FACS,Hon. Professor of Surgery President ECCO - the European Cancer Organization Past-President
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationDifferential effect of concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for locally advanced rectal cancer
JBUON 2019; 24(2): 470-478 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Differential effect of concurrent chemotherapy regimen on clinical outcomes
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationRectal Cancer. Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco
Rectal Cancer Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Modern Treatment for Rectal Cancer Improve Local Control Improved
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationPreoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience)
Original Article Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience) Abeer Hussien Anter 1, Ghada Ezzat Eladawei 2, Mahmoud Mosbah
More informationAdvances in preoperative radiochemotherapy for resectable rectal cancer
[Chinese Journal of Cancer 27:12, 587-591; December Advances 2008]; 2008 in preoperative Sun Yat-sen radiochemotherapy University Cancer for Center resectable rectal cancer Review Advances in preoperative
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationCover Page. Author: Wiltink, Lisette Title: Long-term effects and quality of life after treatment for rectal cancer Issue Date:
Cover Page The handle http://hdl.handle.net/1887/46445 holds various files of this Leiden University dissertation Author: Wiltink, Lisette Title: Long-term effects and quality of life after treatment for
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/887/22038 holds various files of this Leiden University dissertation. Author: Swellengrebel, H.A.M. Title: Challenges in the multimodality treatment of rectal
More informationLatkauskas et al. BMC Cancer (2016) 16:927 DOI /s
Latkauskas et al. BMC Cancer (2016) 16:927 DOI 10.1186/s12885-016-2959-9 RESEARCH ARTICLE reoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer:
More informationNeoadjuvant Therapy for Rectal Cancer is Overrated. Joon H. Lee, Research Resident University of Colorado 8/31/2009
Neoadjuvant Therapy for Rectal Cancer is Overrated Joon H. Lee, Research Resident University of Colorado 8/31/2009 Objectives Brief overview of staging rectal cancer Current guidelines for evaluation and
More informationCREATE Trial Proposal: Survey of current practice and potential trial participation
CREATE Trial Proposal: Survey of current practice and potential trial participation Approximately a quarter of newly diagnosed rectal cancer patients have features on pre-treatment pelvic MRI indicating
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationACR Appropriateness Criteria Resectable Rectal Cancer EVIDENCE TABLE
. National Cancer Institute. Comprehensive Cancer Information. http://www.cancer.gov/cancertopics/types/ colon-and-rectal. Accessed 5 January 202. 2. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM,
More informationLong Term Outcomes of Preoperative versus
RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationA phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer
3114 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(16): 3114-3121. doi: 10.7150/jca.21237 A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationFourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study
Original Article Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study Sezer Saglam 1, Dursun Bugra 2, Esra K. Saglam 3, Oktar Asoglu 4, Emre
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 3 NUMBER 31 NOVEMBER 1 212 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Samuel Y. Ngan, Richard J. Fisher, Bev McClure, Sue-Anne McLachlan, Trevor Leong, John Zalcberg, and John Mackay,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/22038 holds various files of this Leiden University dissertation. Author: Swellengrebel, H.A.M. Title: Challenges in the multimodality treatment of rectal
More informationOutcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study
Original Article Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study Elmer E. van Eeghen 1, Frank den Boer 2, Sandra D. Bakker 1,
More informationNeoadjuvant chemoradiation therapy for rectal cancer: current status and perspectives for the surgeon
Review Article Page 1 of 9 Neoadjuvant chemoradiation therapy for rectal cancer: current status and perspectives for the surgeon Sérgio Eduardo Alonso Araújo 1,2, Guilherme Pagin São Julião 3, Angelita
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationIntroduction. Original Article
Original Article Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? Vikas Ostwal 1, Reena Engineer
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationPre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer
Pre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer DIMITRIS P. KORKOLIS 1, CHRISTOS S. BOSKOS 2, GEORGE D. PLATANIOTIS 1, EMMANUEL GONTIKAKIS 1, IOANNIS
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More information# % & & & ( )!!!!!!!!+,.! / & ( )!!!!!!! +.,,, 0! 1 2 ( ( 8 2 9& :;;!! +.! )!!. 28!!!!!!!!!!!!!+ <! & 69 ; # 8 ; ) 4 = ) # 4 4
! # % & & & ( )!!!!!!!!+,.! / & ( )!!!!!!! +.,,, 0! 1 2 ( 3 4 5 6 7 ( 8 2 9& 0 1 + :;;!! +.! )!!. 28!!!!!!!!!!!!!+ The d-prefix: towards
More informationGrandangolo in Radioterapia Oncologica. D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI
Grandangolo in Radioterapia Oncologica D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI www.radioterapia.unich.it TOPICS ü ESOFAGO & GIUNZIONE ESOFAGO- GASTRICA ü STOMACO ü RETTO ü ANO
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationFausto Petrelli, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Veronica Lonati, Sandro Barni
Original Article Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials Fausto Petrelli, Karen Borgonovo,
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More information